82 related articles for article (PubMed ID: 22931245)
21. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of P-glycoprotein and increasing of drug-sensitivity of a human carcinoma cell line (KB-A-1) by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro.
Ren Y; Wei D; Zhan X
Biotechnol Appl Biochem; 2005 Apr; 41(Pt 2):137-43. PubMed ID: 15202936
[TBL] [Abstract][Full Text] [Related]
23. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
[TBL] [Abstract][Full Text] [Related]
24. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
25. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
26. Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide.
Yang JH; Feng F; Qian H; Cheng H
Breast; 2004 Jun; 13(3):227-31. PubMed ID: 15177426
[TBL] [Abstract][Full Text] [Related]
27. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
28. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
[TBL] [Abstract][Full Text] [Related]
29. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
[TBL] [Abstract][Full Text] [Related]
30. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
[TBL] [Abstract][Full Text] [Related]
31. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C
J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275
[TBL] [Abstract][Full Text] [Related]
32. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
Gokhale PC; McRae D; Monia BP; Bagg A; Rahman A; Dritschilo A; Kasid U
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):191-201. PubMed ID: 10355825
[TBL] [Abstract][Full Text] [Related]
33. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
Chiu SJ; Liu S; Perrotti D; Marcucci G; Lee RJ
J Control Release; 2006 May; 112(2):199-207. PubMed ID: 16564596
[TBL] [Abstract][Full Text] [Related]
34. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression.
Notarbartolo M; Poma P; Perri D; Dusonchet L; Cervello M; D'Alessandro N
Cancer Lett; 2005 Jun; 224(1):53-65. PubMed ID: 15911101
[TBL] [Abstract][Full Text] [Related]
37. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides.
Meyer O; Kirpotin D; Hong K; Sternberg B; Park JW; Woodle MC; Papahadjopoulos D
J Biol Chem; 1998 Jun; 273(25):15621-7. PubMed ID: 9624154
[TBL] [Abstract][Full Text] [Related]
38. Telomerase activity, expression of Bcl-2 and cell cycle regulation in doxorubicin resistant gastric carcinoma cell lines.
Yoon KA; Ku JL; Yang JO; Park JG
Int J Mol Med; 2003 Mar; 11(3):343-8. PubMed ID: 12579337
[TBL] [Abstract][Full Text] [Related]
39. In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate.
Ren Y; Zhan X; Wei D; Liu J
Biomed Pharmacother; 2004 Nov; 58(9):520-6. PubMed ID: 15511610
[TBL] [Abstract][Full Text] [Related]
40. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]